Last reviewed · How we verify

Ropivacaine 0.75%, 20ml

Paracelsus Medical University · FDA-approved active Small molecule Quality 5/100

Ropivacaine 0.75%, 20ml is a Small molecule drug developed by Paracelsus Medical University. It is currently FDA-approved. Also known as: Naropin.

At a glance

Generic nameRopivacaine 0.75%, 20ml
Also known asNaropin
SponsorParacelsus Medical University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ropivacaine 0.75%, 20ml

What is Ropivacaine 0.75%, 20ml?

Ropivacaine 0.75%, 20ml is a Small molecule drug developed by Paracelsus Medical University.

Who makes Ropivacaine 0.75%, 20ml?

Ropivacaine 0.75%, 20ml is developed and marketed by Paracelsus Medical University (see full Paracelsus Medical University pipeline at /company/paracelsus-medical-university).

Is Ropivacaine 0.75%, 20ml also known as anything else?

Ropivacaine 0.75%, 20ml is also known as Naropin.

What development phase is Ropivacaine 0.75%, 20ml in?

Ropivacaine 0.75%, 20ml is FDA-approved (marketed).

Related